On September 6, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, reported abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma (Press release, Harpoon Therapeutics, SEP 6, 2023, View Source [SID1234634956]). The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the IMS poster presentation are as follows:
Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Poster Number: P-292
Presenter: Sumit Madan, M.D., Banner MD Anderson Cancer Center
Session/Location: Poster Session 2, Trianti Hall Level II Foyer
Date: Thursday, September 28
Time: Viewing – 10:00 to 18:15 EEST / 3:00 a.m. to 1:15 p.m. ET, Presentation – 12:30 to 13:30 EEST / 5:30 a.m. to 6:30 a.m. ET
The poster will also be available on Harpoon’s website following the presentation.
For more details about the IMS Annual Meeting, please visit:
View Source;sortMenu=101000